Text: H.R.7104 — 116th Congress (2019-2020)All Information (Except Text)

There is one version of the bill.

Text available as:

Shown Here:
Introduced in House (06/04/2020)

 
[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7104 Introduced in House (IH)]

<DOC>






116th CONGRESS
  2d Session
                                H. R. 7104

     To direct the Secretary of Health and Human Services to award 
  contracts, grants, and cooperative agreements to expand and enhance 
 manufacturing capacity of vaccines and vaccine candidates to prevent 
                 the spread of SARS-CoV-2 and COVID-19.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                              June 4, 2020

 Ms. Kuster of New Hampshire (for herself and Mr. Jeffries) introduced 
 the following bill; which was referred to the Committee on Energy and 
                                Commerce

_______________________________________________________________________

                                 A BILL


 
     To direct the Secretary of Health and Human Services to award 
  contracts, grants, and cooperative agreements to expand and enhance 
 manufacturing capacity of vaccines and vaccine candidates to prevent 
                 the spread of SARS-CoV-2 and COVID-19.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. VACCINE MANUFACTURING AND ADMINISTRATION CAPACITY.

    (a) Enhancing Manufacturing Capacity.--
            (1) In general.--The Secretary of Health and Human Services 
        (in this section referred to as the ``Secretary'') acting 
        through the Director of the Biomedical Advanced Research and 
        Development Authority shall, as appropriate, award contracts, 
        grants, and cooperative agreements, and enter into other 
        transactions, to expand and enhance manufacturing capacity of 
        vaccines and vaccine candidates to prevent the spread of SARS-
        CoV-2 and COVID-19.
            (2) Authorization of appropriations.--To carry out this 
        subsection, there are authorized to be appropriated such sums 
        as may be necessary for fiscal years 2020 through 2024, to 
        remain available until expended.
    (b) Report on Vaccine Manufacturing and Administration Capacity.--
            (1) In general.--Not later than December 31, 2020, the 
        Secretary shall submit to the Committee on Energy and Commerce 
        of the House of Representatives and the Committee on Health, 
        Education, Labor and Pensions of the Senate a report 
        detailing--
                    (A) an assessment of the estimated supply of 
                vaccines and ancillary medical products related to 
                vaccine administration necessary to control and stop 
                the spread of SARS-CoV-2 and COVID-19, domestically and 
                internationally;
                    (B) an assessment of current and future domestic 
                manufacturing capacity for vaccines or vaccine 
                candidates to control or stop the spread of SARS-CoV-2 
                and COVID-19, vaccine candidates, and ancillary 
                products related to the administration of such 
                vaccines, including identification of any gaps in 
                manufacturing capacity;
                    (C) activities conducted to expand and enhance 
                manufacturing capacity for vaccines, vaccine 
                candidates, and ancillary medical products to levels 
                sufficient to control and stop the spread of SARS-CoV-2 
                and COVID-19, domestically and internationally, 
                including a list and explanation of all contracts, 
                grants, and cooperative agreements awarded, and other 
                transactions entered into, for purposes of such 
                expansion and enhancement and how such activities will 
                help to meet future domestic manufacturing capacity 
                needs;
                    (D) a plan for the ongoing support of enhanced 
                manufacturing capacity for vaccines, vaccine 
                candidates, and ancillary medical products sufficient 
                to control and stop the spread of SARS-CoV-2 and COVID-
                19, domestically and internationally; and
                    (E) a plan to support the administration of 
                vaccines approved or authorized by the Food and Drug 
                Administration to control and stop the spread of SARS-
                CoV-2 and COVID-19, domestically and internationally, 
                including Federal workforce enhancements necessary to 
                administer such vaccines.
            (2) Ancillary medical products.--For purposes of this 
        subsection, ``ancillary medical products'' includes--
                    (A) vials;
                    (B) bandages;
                    (C) alcohol swabs;
                    (D) syringes;
                    (E) needles;
                    (F) gloves and other personal protective equipment; 
                and
                    (G) other medical products the Secretary determines 
                necessary for the administration of vaccines.
                                 <all>

Share This